Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials

The Lancet

Volumn 384, Issue 9958, 2014, Pages 1929-1935

  Emberson, Jonathan ^a   Lees, Kennedy R ^b   Lyden, Patrick ^c   Blackwell, Lisa ^a   Albers, Gregory ^d   Bluhmki, Erich ^e   Brott, Thomas ^f   Cohen, Geoff ^g   Davis, Stephen ^h   Donnan, Geoffrey ⁱ   Grotta, James ^j   Howard, George ^k   Kaste, Markku ^l   Koga, Masatoshi ^m   Von Kummer, Ruediger ⁿ   Lansberg, Maarten ^d   Lindley, Richard I ^o   Murray, Gordon ^g   Olivot, Jean Marc ^d   Parsons, Mark ^p   Tilley, Barbara ^j   Toni, Danilo ^q   Toyoda, Kazunori ^m   Wahlgren, Nils ^r   Wardlaw, Joanna ^g   Whiteley, William ^g   Del Zoppo, Gregory J ^s   Baigent, Colin ^a   Sandercock, Peter ^g   Hacke, Werner ^t   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^j UNIVERSITY OF TEXAS   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁿ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^o UNIVERSITY OF SYDNEY   (Australia)

^p UNIVERSITY OF NEWCASTLE   (Australia)

^q SAPIENZA UNIVERSITY OF ROME   (Italy)

^r KAROLINSKA INSTITUTE   (Sweden)

^s UNIVERSITY OF WASHINGTON   (United States)

^t UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; THERAPY; THERAPY DELAY; ACUTE DISEASE; AGED; CHEMICALLY INDUCED; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; STROKE; TIME TO TREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84919432580     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60584-5     Document Type: Article

References (32)

1. W Hacke, G Donnan, C Fieschi the ATLANTIS Trials Investigators the ECASS Trials Investigators the NINDS rt-PA Study Group Investigators Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 363 2004 768 774
2. KR Lees, E Bluhmki, R von Kummer for the ECASS ATLANTIS NINDS and EPITHET rt-PA Study Group Investigators Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 375 2010 1695 1703
3. European Stroke Organisation (ESO) Executive Committee the ESO Writing Committee Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 Cerebrovasc Dis 25 2008 457 507
4. European Stroke Organisation guidelines for stroke management: Update January 2009 Available from: http://www.eso-stroke.org/eso-stroke/education/education-guidelines.html (accessed March 3, 2014).
5. K Minematsu, K Toyoda, T Hirano et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society J Stroke Cerebrovasc 22 2013 571 600
6. Australian Stroke Foundation Clinical guidelines for stroke management 2010 http://strokefoundation.com.au/site/media/Clinical-Guidelines-Acute-Management-Recommendations-2010.pdf (accessed March 3, 2014).
7. Summary of product characteristics (alteplase) http://www.medicines.org.uk/EMC/medicine/308/SPC/Actlyse (accessed March 3, 2014).
8. Australian Government Department of Health Therapeutic Goods Administration Product and Consumer Medicine Information. Actilyse https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=Actilyse&r=https://www.ebs.tga.gov.au/ (accessed March 3, 2014).
9. Genentech Activase (Alteplase) http://www.gene.com/download/pdf/activase-prescribing.pdf (accessed March 3, 2014).
10. GA Ford, N Ahmed, E Azevedo et al. Intravenous alteplase for stroke in those older than 80 years old Stroke 41 2010 2568 2574
11. NK Mishra, N Ahmed, G Andersen the VISTA collaborators the SITS collaborators Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive BMJ 341 2010 c6046
12. NK Mishra, HC Diener, PD Lyden, E Bluhmki, KR Lees the VISTA Collaborators Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA) Stroke 41 2010 2840 2848
13. P Sandercock, JM Wardlaw, RI Lindley the IST-3 collaborative group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial Lancet 379 2012 2352 2363
14. W Hacke, M Kaste, C Fieschi the European Cooperative Acute Stroke Study (ECASS) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke JAMA 274 1995 1017 1025
15. W Hacke, M Kaste, C Fieschi et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet 352 1998 1245 1251
16. W Hacke, M Kaste, E Bluhmki the ECASS Investigators Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
17. SM Davis, GA Donnan, MW Parsons the EPITHET investigators Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial Lancet Neurol 7 2008 299 309
18. WM Clark, S Wissman, GW Albers, JH Jhamandas, KP Madden, S Hamilton for the ATLANTIS Study Investigators Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial JAMA 282 1999 2019 2026
19. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
20. JM Wardlaw, V Murray, E Berge et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis Lancet 379 2012 2364 2372
21. J Emberson, KR Lees, G Howard the Stroke Thrombolysis Trialists' Collaborative Group Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis Int J Stroke 8 2013 278 283
22. N Wahlgren, N Ahmed, A Dávalos et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study Lancet 369 2007 275 282
23. D Schoenfeld Partial residuals for the proportional hazards regression-model Biometrika 69 1982 239 241
24. J Carpenter, J Bithell Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians Stat Med 19 2000 1141 1164
25. EC Haley Jr, TG Brott, GL Sheppard the TPA Bridging Study Group Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke Stroke 24 1993 1000 1004
26. E Mori, Y Yoneda, M Tabuchi et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke Neurology 42 1992 976 982
27. SY Wang, XL Wang, H Zeng et al. Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 15 2003 542 545 (published in Chinese).
28. T Yamaguchi, T Hayakawa, H Kiuchi Intravenous Tissue-plasminogen activator ameliorates the outcome of hyperacute embolic stroke Cerebrovasc Dis 3 1993 269 272
29. TM Hemmen, R Raman, KZ Guluma the ICTuS-L Investigators Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results Stroke 41 2010 2265 2270
30. The NINDS t-PA Stroke Study Group Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial Stroke 28 1997 2119 2125
31. B Frank, RL Fulton, KR Lees for the VISTA Collaborators The effect of time to treatment on outcome in very elderly thrombolysed stroke patients Int J Stroke 2014 10.1111/ijs.12249 published online March 3.
32. G Howard, DC Goff Population shifts and the future of stroke: forecasts of the future burden of stroke Ann N Y Acad Sci 1268 2012 14 20